MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Valence Discovery (“Valence”), an emerging leader in AI-enabled drug design, announced today a multi-target discovery collaboration leveraging Valence’s platform for generative drug design with Servier, a global pharmaceutical company.

Read More